Benzinga
Benzinga
Benzinga
mercoledì, settembre 30

Viatris Inc

VTRSNASDAQ
Trade with Public
Trade with Public
$17.95
-0.18-0.97%
Ult. Agg.: Sep 30, 10:08 AM
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Viatris Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viatris (VTRS).

Price Target Range — 10 Quarters

Analyst Consensus — 10 Analysts

6Buy
3Hold
1Sell
Consensus RatingBuy# Analysts10Avg. Consensus PT$16Upside to Avg. PT-9.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 23, 2026OppenheimerLes SulewskiInitiateOutperform$25
Sep 16, 2026Piper SandlerDavid AmsellemPT RaiseNeutral$12→$13
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Oppenheimer analyst Les Sulewski initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $25.
Benzinga Newsdesk

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.
Avi Kapoor

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.
Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

Leerink Partners analyst Daniel Clark initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $20.
Benzinga Newsdesk

PRO
Argus Research Maintains Buy on Viatris, Raises Price Target to $20

Argus Research analyst Jasper Hellweg maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $15 to $20.
Benzinga Newsdesk

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ratings page provides latest analyst takes on top stocks, sorted by accuracy. Ratings for three high-yielding health care stocks: VTRS, MDT, GSK. VTRS to report Q2 results on Aug.6, MDT recalls certain catheter system, GSK reports positive trial results. Benzinga Pro's newsfeed provides real-time alerts.
Avi Kapoor

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved